Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
2
clinical trials
|
View Analysis
Sort by:
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: SH-1028 tablets
Drug: Placebo SH-1028 tablets
Subscribe
First Posted Date
2023-10-12
Last Posted Date
2023-10-12
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Target Recruit Count
242
Registration Number
NCT06080776
Locations
🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Subscribe
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: SH-1028 tablets
Drug: Placebo SH-1028 tablets
Drug: Placebo Gefitinib
Drug: Gefitinib
Subscribe
First Posted Date
2020-01-27
Last Posted Date
2020-01-27
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Target Recruit Count
240
Registration Number
NCT04239833
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy